DexCom, Inc. (Nasdaq: DXCM) Thursday reported its financial results as of and for the quarter ended September 30, 2021.
Third Quarter 2021 Financial Highlights:
Revenue grew 30% versus the same quarter of the prior year to $650.2 million on a reported basis and 28% on an organic1 basis.
U.S. revenue growth of 23% and international revenue growth of 57% on a reported basis. International growth was 46% on an organic1 basis.
GAAP operating income of $118.3 million or 18.2% of revenue, a decrease of 60 basis points compared to the third quarter of 2020. Non-GAAP operating income* of $123.8 million or 19.0% of revenue, in line with the same quarter of the prior year.
Strategic Highlights:
Received FDA clearance for two key software solutions that enhance Dexcom’s connected ecosystem:
The Dexcom real-time API makes it possible for third-party developers to integrate real-time CGM data into their digital health apps and devices, ultimately offering Dexcom users a greater variety of options in where and how they engage with their glucose data.2
The Dexcom app-in-app module directly integrates with third party healthcare apps, making managing diabetes easier for Type 2 Non-intensive insulin therapy (NIIT) users by enabling a convenient, single-app experience.
Completed the acquisition of our distributor in Australia and New Zealand, advancing Dexcom’s strategy to transition certain international markets from distributors to direct sales.
Introduced a new product with the launch of Dexcom ONE, a key addition to our portfolio as we seek to broaden access to healthcare for people with diabetes globally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.